尽管2025年上半年业绩出现下滑，神威药业（02877）今日盘中股价却大涨5.39%，引发市场关注。该公司刚刚公布的中期业绩显示，虽然收入和利润均有所下降，但整体表现似乎优于市场预期。
根据公告，神威药业2025年上半年收益为16.53亿元人民币，同比下降20.8%；期内溢利为6.15亿元人民币，同比小幅下降1.89%。值得注意的是，尽管业绩下滑，公司仍维持每股11分人民币的中期股息，与去年同期持平，显示出管理层对公司未来发展的信心。
分析人士指出，神威药业在收入大幅下滑的情况下，净利润仅小幅下降，反映出公司良好的成本控制能力。虽然毛利率从去年同期的75.3%下降至72.2%，但仍保持在较高水平。这些因素可能是投资者看好该股的原因，推动股价上涨。此外，市场可能认为公司在当前经济环境下的表现已经相对不错，预期未来业绩有望改善，从而带动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.